Cancer immunoinoculation in the mouse model - mfd Diagnostics makes a decisive contribution

Immunotherapies show efficacy in previously therapy-resistant cancers and have a very large application and market potential. The development, validation and clinical translation of new immunotherapies against cancer is therefore of great medical and economic importance. In order to produce optimal cancer vaccines, mfd Diagnostics GmbH has successfully carried out various preliminary work for the development of technologies for cell disruption using ultrashort pulse lasers.

The collaborative project "ImmuVak", which was completed at the beginning of the year, aimed to use these technologies to develop a method for efficient and gentle cell disruption and cancer immunoaccination based on it in a mouse model. In cooperation with the Institute for Translational Immunology of the Johannes Gutenberg University Mainz, various process parameters have been tested and optimized for several cancer cell lines in in-vitro as well as in-vivo studies. The effect of the immunotherapy could be demonstrated in the in-vivo studies by growth kinetics of subcutaneous injection experiments.

The cooperation project was financially supported by the BMWi as part of the Central Innovation Program for SMEs (ZIM).